HF  Surveyor Capital

https://www.citadel.com/investment-strategies /surveyor-capital/





     Office Locations:

300 Crescent Court, Suite 250
Dallas, TX 75201
Phone: 972-892-1700

Get all office locations for this firm with a National Database subscription or New York Database subscription.
 

Stages:

  • Early


 

Industries:

  • Life Sciences & Healthcare
  • Medical Device

  •  

    Description:

    Established in 2008, Surveyor Capital is a global, multi-manager equities strategy and is one of Citadel Investment's three fundamental equities businesses. Surveyor's independent sector-aligned portfolio teams take a diligent, bottom-up investment approach. Citadel invests in companies in the Communications, Consumer, Energy, Financials, Healthcare, Industrials, Media and Entertainment, and Technology sectors.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or New York Database subscription.
    Khalid Malik Portfolio Manager
    Rich Falk-Wallace Portfolio Manager
    Tariq Chaudhri Portfolio Manager
    Todd Barker Head of Surveyor Capital

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      03/02/2021


      Artiva Biotherapeutics


      CA


      $120,000,000


      Series B


      02/24/2021


      Vividion Therapeutics


      CA


      $135,000,000


      Series C


      01/22/2021


      Vera Therapeutics


      CA


      $80,000,000


      Series C


      01/19/2021


      Verve Therapeutics


      MA


      $94,000,000


      Series B


      12/16/2020


      Neuron23


      CA


      $113,500,000


      Series A and B


      11/09/2020


      Decibel Therapeutics


      MA


      $82,000,000


      Series D


      10/06/2020


      Talaris Therapeutics


      MA


      $115,000,000


      Series B


      09/17/2020


      Palleon Pharmaceuticals


      MA


      $100,000,000


      Series B


      09/14/2020


      ESCAPE Bio


      CA


      $73,000,000


      Crossover Financing


      08/27/2020


      Kinnate Biopharma


      CA


      $98,000,000


      Series C


      08/10/2020


      Dyne Therapeutics


      MA


      $115,000,000


      


      08/07/2020


      Aerovate Therapeutics


      MA


      $72,600,000


      Series A


      07/30/2020


      Praxis Precision Medicines


      MA


      $110,000,000


      Series C-1


      07/24/2020


      Olema Oncology


      CA


      $54,000,000


      Series B


      07/09/2020


      VelosBio


      CA


      $137,000,000


      Series B


      07/02/2020


      Bolt Biotherapeutics


      CA


      $93,500,000


      Series C


      07/02/2020


      Annexon Biosciences


      CA


      $100,000,000


      Venture


      06/04/2020


      Athira Pharma


      WA


      $85,000,000


      Series B


      03/30/2020


      ElevateBio


      MA


      $170,000,000


      Series B


      03/03/2020


      Pliant Therapeutics


      CA


      $100,000,000


      Series C


     

    Portfolio companies include:

     

    Recent News: